title: Increased myocardial dysfunction after ischemia-reperfusion in mice lacking glucose-6-phosphate dehydrogenase.
abstract: BACKGROUND
  Free radical injury contributes to cardiac dysfunction during ischemia-reperfusion. Detoxification of free radicals requires maintenance of reduced glutathione (GSH) by NADPH. The principal mechanism responsible for generating NADPH and maintaining GSH during periods of myocardial ischemia-reperfusion remains unknown. Glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme in the pentose phosphate pathway, generates NADPH in a reaction linked to the de novo production of ribose. We therefore hypothesized that G6PD is essential for maintaining GSH levels and protecting the heart during ischemia-reperfusion injury.
  
  
  RESULTS
  Susceptibility to myocardial ischemia-reperfusion injury was determined in Langendorff-perfused hearts isolated from wild-type mice (WT) and mice lacking G6PD (G6PD(def)) (20% of WT myocardial G6PD activity). During global zero-flow ischemia, cardiac function was similar between WT and G6PD(def) hearts. On reperfusion, however, cardiac relaxation and contractile performance were greatly impaired in G6PD(def) myocardium, as demonstrated by elevated end-diastolic pressures and decreased percent recovery of developed pressure relative to WT hearts. Contractile dysfunction in G6PD(def) hearts was associated with depletion of total glutathione stores and impaired generation of GSH from its oxidized form. Increased ischemia-reperfusion injury in G6PD(def) hearts was reversed by treatment with the antioxidant MnTMPyP but unaffected by supplementation of ribose stores.
  
  
  CONCLUSIONS
  These results demonstrate that G6PD is an essential myocardial antioxidant enzyme, required for maintaining cellular glutathione levels and protecting against oxidative stress-induced cardiac dysfunction during ischemia-reperfusion.
authors.affiliation: Whitaker Cardiovascular Institute and Evans Department of Medicine, Boston University School of Medicine, Boston, Mass 02118, USA.
authors.forename: Mohit
authors.initials: M
authors.lastname: Jain
authors.forename: Lei
authors.initials: L
authors.lastname: Cui
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Brenner
authors.forename: Bo
authors.initials: B
authors.lastname: Wang
authors.forename: Diane E
authors.initials: DE
authors.lastname: Handy
authors.forename: Jane A
authors.initials: JA
authors.lastname: Leopold
authors.forename: Joseph
authors.initials: J
authors.lastname: Loscalzo
authors.forename: Carl S
authors.initials: CS
authors.lastname: Apstein
authors.forename: Ronglih
authors.initials: R
authors.lastname: Liao
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005838:Genotype; D005954:Glucosephosphate Dehydrogenase / Q000235:genetics / Q000502:physiology*; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000150:complications*; D005978:Glutathione / Q000378:metabolism; D008297:Male; D008665:Metalloporphyrins / Q000494:pharmacology / Q000627:therapeutic use; D051379:Mice; D018345:Mice, Knockout; D009200:Myocardial Contraction / Q000187:drug effects / Q000502:physiology*; D017202:Myocardial Ischemia / Q000201:enzymology / Q000235:genetics* / Q000503:physiopathology; D015428:Myocardial Reperfusion Injury / Q000201:enzymology / Q000235:genetics* / Q000503:physiopathology; D009249:NADP / Q000502:physiology; D010084:Oxidation-Reduction; D012266:Ribose / Q000172:deficiency / Q000494:pharmacology
chemical_list: D000975:Antioxidants; D008665:Metalloporphyrins; D009249:NADP; D012266:Ribose; C050950:tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex; D005954:Glucosephosphate Dehydrogenase; D005978:Glutathione